[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ulcer-gastric\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ulcer-gastric":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,60,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100557838","marginal-ulcer-healing-with-low-thermal-argon-plasma-endoscopic-treatment-100557838",false,"NCT06543316","Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","Accelerated Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment","AMULET","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with a history of Roux-en-Y gastric bypass (RYGB) presenting symptoms indicative of marginal ulcers (MUs) such as abdominal pain, nausea, vomiting, gastrointestinal bleeding, or dysphagia.\n* Subjects must be scheduled for an EGD for the evaluation of these symptoms.\n* Marginal ulcers confirmed during the initial EGD.\n* Willingness to adhere to the SOC treatment, which includes PPIs.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent and understanding of study requirements.\n* Willingness and ability to attend required follow-up assessments at 4 weeks (+\u002F- 1 week) and 8 weeks (+\u002F- 2 weeks).\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Inability or unwillingness to comply with the SOC.\n* Current use of systemic antibiotics.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (\\~ 1 W) we hypothesize that the size of the ulcers will shrink, and the healing is accelerated compared to standard of care alone. Patients will benefit from this minimally invasive approach compared to a much more invasive surgical approach that comes with higher risks and hospital stay length time. From a societal and scientific perspective, this study aims to extend the well-documented clinical benefits of plasma technology - from external wound healing to internal ulcer treatment - within an endoscopic framework. The success of this study could pave the way for broader applications of LTP in the treatment of other endoscopically accessible conditions such as peptic ulcers, duodenal ulcers and esophageal ulcers. This advancement has the potential not only to improve patient outcomes through less invasive methods, but also to position LTP as a cornerstone in the future of gastroenterological wound management strategies.",[27,28,29,30,31,32,33,34,35,36,37,38],"Roux-en-y Anastomosis Site","Marginal Ulcer","Marginal Ulcer (Peptic) or Erosion","Ulcer","Ulcer, Gastric","Ulcer Gastrointestinal","Abdominal Pain","Nausea","Vomiting","GastroIntestinal Bleeding","Dysphagia","Ulcer Gastrojejunal",[40,41,42,43,44,45,46],"Argon Plasma Coagulation","APC","Low-Thermal Argon Plasma Endoscopic Treatment","Endoscopy","RYGB","Roux-en-Y Gastric Bypass","Ulcer Healing","RECRUITING","2026-06-23",{"date":50,"type":51},"2026-06-25","ACTUAL",{"date":53,"type":51},"2025-03-04",{"date":55,"type":21},"2028-06",{"name":57,"class":58},"Christopher C. Thompson, MD, MSc","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":59},"100463907","phase-4-the-bioavailability-and-effect-on-pouch-ph-of-esomeprazole-after-gastric-bypass-100463907","NCT05320796","The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass","The Bioavailability and Effect on Pouch pH of Esomeprazole as Tablets or in Solution After Laparoscopic Proximal RYGB for Morbid Obesity - an Investigator Blinded Pilot Study","Inclusion Criteria:\n\n* Proximal Roux-en-Y gastric bypass with linear stapled anastomosis 12 months prior to the study investigation\n* Routine administration of proton pump inhibitors for 6 months postoperatively\n* No intake of proton pump inhibitors at least 4 weeks prior to study investigation\n* No marginal ulcers in upper endoscopy prior to placement of wireless BRAVO™ pH monitoring capsule\n* No symptoms related to gastro-esophageal reflux or marginal ulcers (i.e. epigastric pain, retrosternal burning, regurgitation)\n* Informed consent as documented by signature\n\nExclusion Criteria:\n\n* Known intolerance or allergy for Esomeprazol\n* Contraindication for upper endoscopy\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant\n* Women who are pregnant or breast feeding Major hepatic dysfunction",{"count":68,"type":21},50,[70],"PHASE4","The objective of this study is to investigate the effect of Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water) on acid production in the gastric pouch by measuring the intragastric pH and the serum concentration of esomeprazole.",[73,74,31],"Obesity","Gastric Reflux","2026-06-08",{"date":77,"type":51},"2026-06-09",{"date":79,"type":51},"2023-11-01",{"date":81,"type":21},"2027-12-31",{"name":83,"class":58},"Prof Urs Zingg",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":59},"100394925","functional-changes-in-the-stomach-and-esophagus-after-one-anastomosis-gastric-bypass--oagb-100394925","NCT04422405","Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB","Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB- BiFlux Trial","BiFLux","Inclusion Criteria:\n\n* BMI\\> 35 kg\u002Fm2\n* 2 years of controlled conservative obesity treatment without weight reduction\n* patients should give their consent to participate in the study\n\nExclusion Criteria:\n\n* Less than 2 years of conservative obesity treatment\n* cancer\n* cirrhosis Child-Pough score A\n* Crohn's disease\n* serious psychiatric disorder, which led to in-hospital treatment in psychiatric clinic in the past two years\n* drug consumption\n* non-compliance\n* hiatal hernia \\> 4cm\n* gastric pouch \\\u003C 10cm\n* Barett esophagus\n* erosive esophagitis Grade C or D according to the Los Angeles Classification\n* endoscopically proven gastric stricture\n* acid exposition time \\> 6% (Lyon criteria)\n* reflux episodes\\> 80 \u002F24 hours (Lyon criteria)\n* insufficient low esophageal sphincter according to manometry findings\n* pathological findings in the impedance pH-metry (acid and non-acid reflux)","65 Years",{"count":94,"type":21},300,[24],"Evaluation of the functional changes in the stomach and esophagus of patients undergoing One Anastomosis Gastric Bypass (OAGB)",[98,99,31],"Obesity, Morbid","GERD","2025-06-03",{"date":102,"type":51},"2025-06-06",{"date":104,"type":51},"2020-06-01",{"date":106,"type":21},"2035-05-28",{"name":108,"class":58},"Spital Limmattal Schlieren"]